Evaxion A (EVAX) Income from Non-Controlling Interests (2020 - 2022)
Evaxion A (EVAX) posted Income from Non-Controlling Interests of -$602000.0 for Q1 2022, up 26.76% on a QoQ basis from -$822000.0 in Q3 2021, and up 18.1% year-over-year from -$509758.1 in Q1 2021.
Evaxion A (EVAX) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Evaxion A's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$602000.0 for Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -602,000.00 |
| Sep 30, 2021 | -822,000.00 |
| Jun 30, 2021 | 423,000.00 |
| Mar 31, 2021 | -735,000.00 |
| Sep 30, 2020 | 88,000.00 |
| Jun 30, 2020 | 99,000.00 |
| Mar 31, 2020 | -180,000.00 |